6 May 2022 – The amazing advances in gene sequencing technology over the last two decades have not yet sparked the revolution in personalized cancer treatment that many had hoped for. Although there have been significant advances, actionable mutations, those that can be targeted to improve patient survival or quality of life, remain rare. But there is also the option to leapfrog genomics entirely, or to complement it, by using proteomic approaches. You may be surprised to learn that, as the guests on this episode of our podcast, Ursula Klingmüller and Matthias Mann told us, clinical proteomics is already being explored to design personalized cancer treatment strategies. Klingmüller and Mann discussed the technological (read the Mann lab’s recent Molecular Systems Biology paper on single cell proteomics here), scientific, and clinical challenges of the field with Molecular Systems Biology Senior Scientific Editor Maria Polychronidou.
